Skip to main content

Table 3 Factors associated with overall, disease-free, pulmonary progression-free, and systemic treatment free survivals after radiofrequency ablation of lung metastases from renal cell carcinoma (n = 53)

From: Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience

 Overall SurvivalPulmonary Progression-free survivalSystemic Treatment-free survivalDisease-free survival
UnivariateMultivariableUnivariateMultivariableUnivariateMultivariableUnivariateMultivariable
P (Log-Rank)HR (95%CI)PHR (95%CI)PP P
Sex
 Male0.94 0.310.570.53
 Female   2.7 (1.04–7.2) (P = 0.042)    
Age at RFA
  ≤ 60 years0.670.440.660.94
  < 60 years        
Concomitant metastases
 Yes0.870.850.710.81
 No        
Extra-thoracic metastases
 Yes0.860.730.790.72
 No        
T staging
 T1-T20.0311 (Ref.)0.0241 (Ref.)0.0471 (Ref.)0.07
 T3-T4 3.55 (1.05–12.1) (P = 0.04) 3.5 (1.3–9.3) (P = 0.011) 2.3 (1–5.5) (P = 0.053)  
Fuhrman
 1–20.310.490.260.71
 3–4        
Lung mets size
  ≤ 20 mm 1 (Ref.)0.730.170.39
  > 20 mm0.0192.56 (0.88–7.5) (P = ns)      
Number of lung metastases
 10.690.0071 (Ref.)0.600.14
 2   3.09 (1.1–8.7) (P = 0.032)    
3   3.4 (1.3–9) (P = 0.013)